Extensive dissemination activities were carried out in year 4. A total of 15 articles in peer-reviewed journals and 10 papers have been produced from March 2013 and February 2014. Many dissemination activities were also organised at national and international levels to address other project stakeholders (i.e. cardiologists, industry, medical professional, policy makers), including the civil society. As far as exploitation is concerned, the ownership of the foreground was eventually defined by the project partners, through the definition of Shares, but only for Stand Alone Modules. The consortium agreed that at the moment, it is not possible yet to reach a realistic level of joint ownership % for Combined Modules. In order to assign an IPR weight % the feed-back of VAD producers is needed. The SensorART consortium identified three possible combinations of modules (defined as Exploitable Packages) which could reach an advanced and qualified prototype level in order to address their respective market segments: Implantable Platform for the sensorized VAD market, Monitoring-Control and Decision Support platform for clinical and VAD data and settings for the advanced telemedicine market, and finally Training and Simulation Platform for the training and simulation market segment. As regards IPR, due to current nature of prototypes of the developed technologies, the lack of validation and certification, it is still too early to address the protection of IPR. The consortium agreed that it is not possible to define at the moment who will be the leader entitled to apply for patent. Also this decision will follow the "market feedback" rule established for the IPR shares. Finally, it is worth noticing that in the light of the recent acquisition of CircuLite® by the American company HeartWare®, a specific exploitation plan for the partner CircuLite could not be included in this last document.
D2.4 Dissemination Activities and Exploitation Plan
Pericle Salvini;Maria Giovanna Trivella
2014
Abstract
Extensive dissemination activities were carried out in year 4. A total of 15 articles in peer-reviewed journals and 10 papers have been produced from March 2013 and February 2014. Many dissemination activities were also organised at national and international levels to address other project stakeholders (i.e. cardiologists, industry, medical professional, policy makers), including the civil society. As far as exploitation is concerned, the ownership of the foreground was eventually defined by the project partners, through the definition of Shares, but only for Stand Alone Modules. The consortium agreed that at the moment, it is not possible yet to reach a realistic level of joint ownership % for Combined Modules. In order to assign an IPR weight % the feed-back of VAD producers is needed. The SensorART consortium identified three possible combinations of modules (defined as Exploitable Packages) which could reach an advanced and qualified prototype level in order to address their respective market segments: Implantable Platform for the sensorized VAD market, Monitoring-Control and Decision Support platform for clinical and VAD data and settings for the advanced telemedicine market, and finally Training and Simulation Platform for the training and simulation market segment. As regards IPR, due to current nature of prototypes of the developed technologies, the lack of validation and certification, it is still too early to address the protection of IPR. The consortium agreed that it is not possible to define at the moment who will be the leader entitled to apply for patent. Also this decision will follow the "market feedback" rule established for the IPR shares. Finally, it is worth noticing that in the light of the recent acquisition of CircuLite® by the American company HeartWare®, a specific exploitation plan for the partner CircuLite could not be included in this last document.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
